Your browser doesn't support javascript.
loading
Hospital-associated venous thromboembolism prophylaxis use by risk assessment at a large integrated health care network in Northern California.
Xu, James; Neeman, Elad; Thai, Khanh K; Mishra, Pranita; Schlessinger, David; Clancy, Heather; Myers, Laura; Roubinian, Nareg; Liu, Vincent; Liu, Raymond.
Afiliação
  • Xu J; Internal Medicine, Kaiser Foundation Hospitals, San Francisco, California, USA.
  • Neeman E; Department of Hematology and Oncology, The Permanente Medical Group, San Rafael, California, USA.
  • Thai KK; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Mishra P; Blue Shield of California, Oakland, California, USA.
  • Schlessinger D; Department of Pulmonary/Critical Care, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.
  • Clancy H; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Myers L; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Roubinian N; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Liu V; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Liu R; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
J Hosp Med ; 19(6): 449-459, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38606546
ABSTRACT

BACKGROUND:

Hospital-acquired venous thromboembolism (HA VTE) is a preventable complication in hospitalized patients.

OBJECTIVE:

We aimed to examine the use of pharmacologic prophylaxis (pPPX) and compare two risk assessment methods for HA VTE a retrospective electronic Padua Score (ePaduaKP) and admitting clinician's choice of risk within the admission orderset (low, moderate, or high). DESIGN, SETTINGS AND

PARTICIPANTS:

We retrospectively analyzed prophylaxis orders for adult medical admissions (2013-2019) at Kaiser Permanente Northern California, excluding surgical and ICU patients. INTERVENTION ePaduaKP was calculated for all admissions. For a subset of these admissions, clinician-assigned HA VTE risk was extracted. MAIN OUTCOME AND

MEASURES:

Descriptive pPPX utilization rates between ePaduaKP and clinician-assigned risk as well as concordance between ePaduaKP and clinician-assigned risk.

RESULTS:

Among 849,059 encounters, 82.2% were classified as low risk by ePaduaKP, with 42.3% receiving pPPX. In the subset with clinician-assigned risk (608,512 encounters), low and high ePaduaKP encounters were classified as moderate risk in 87.5% and 92.0% of encounters, respectively. Overall, 56.7% of encounters with moderate clinician-assigned risk received pPPX, compared to 7.2% of encounters with low clinician-assigned risk. pPPX use occurred in a large portion of low ePaduaKP risk encounters. Clinicians frequently assigned moderate risk to encounters at admission irrespective of their ePaduaKP risk when retrospectively examined. We hypothesize that the current orderset design may have negatively influenced clinician-assigned risk choice as well as pPPX utilization. Future work should explore optimizing pPPX for high-risk patients only.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tromboembolia Venosa Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Hosp Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tromboembolia Venosa Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: J Hosp Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos